Dissecting Mayo V. Prometheus

Law360, New York (March 20, 2012, 7:46 PM EDT) -- On March 20, 2012, the U.S. Supreme Court unanimously reversed the Court of Appeals for the Federal Circuit holding that Prometheus's patents — claiming methods for determining the optimal dosages of thiopurine drugs to treat certain diseases — were directed to nonstatutory subject matter pursuant to 35 U.S.C. § 101 and therefore not patent-eligible. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. ___ (2012).

The Supreme Court's opinion is its second recent major decision in the field of patent-eligible subject matter of method

claims and...
To view the full article, register now.